Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173216 | 0.83 | GSK3B (0.61) | GSK3BCYP2D6 | |
| SCHEMBL9944038 | 0.82 | GSK3B (0.60) | GSK3BCYP2D6 | |
| SCHEMBL137966 | 0.82 | GSK3B (0.60) | GSK3BCYP2D6 | |
| SCHEMBL9906429 | 0.82 | GSK3B (0.60) | GSK3BCYP2D6 | |
| SCHEMBL497227 | 0.80 | GSK3B (0.52) | GSK3B | |
| SCHEMBL12207252 | 0.79 | GSK3B (0.57) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3139329 | 0.79 | GSK3B (0.57) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL15135440 | 0.79 | GSK3B (0.54) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3135002 | 0.78 | GSK3B (0.56) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL13046399 | 0.78 | GSK3B (0.56) | GSK3BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006232-B2 | Pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-1572681-B1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8518939-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518939-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-1608630-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1427709-B1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORP (JP) | 2005-12-14 | — | — | EP | disclosed |
| EP-1603910-A1 | SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2005-12-14 | — | — | EP | disclosed |
| US-20050130967-A1 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-06-16 | — | — | US | disclosed |
| CN-1555367-A | 3-substituted-4-pyrimidone derivatives | ������ҩ��ʽ���� | 2004-12-15 | — | — | CN | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004078759-A1 | SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | WO | disclosed |
| EP-1454910-A1 | Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | SANOFI-SYNTHELABO (FR) | 2004-09-08 | — | — | EP | disclosed |
| EP-1427709-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003027080-A1 | 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130967-A1 | 3-Substituted-4-pyrimidone derivatives | TTBK1, CDK1, MAPT | GSK3B 172/4885CYP2D6 2047/4885CYP1A2 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.